文献速递其他结缔组织病

修订版EUSTAR活动指数是系统性硬化症短期严重度累积的最佳预测指标

Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.
PubMed 文献 · Ann Rheum Dis · 2019-08-17

该研究基于EUSTAR数据库549例病程≤5年的系统性硬化症患者,比较修订版EUSTAR活动指数(EUSTAR-AI)与EScSG-AI及已知不良预后因素对2年内疾病严重度累积的预测价值。多因素分析显示,仅EUSTAR-AI调整均值可预测任何严重度累积及肺、心、皮肤和外周血管病变的严重度累积。

要点

  • EUSTAR-AI调整均值是2年内任何严重度累积的唯一预测因素。
  • EUSTAR-AI调整均值可预测肺、心、皮肤和外周血管病变的严重度累积。
  • EUSTAR-AI预测短期疾病进展优于EScSG-AI及已知不良预后因素。

核心结论

  • EUSTAR-AI调整均值对系统性硬化症疾病进展和严重器官受累发展具有最佳预测价值。

研究设计与样本

  • 从EUSTAR数据库提取病程≤5年且基线访视在2003至2014年间的549例系统性硬化症患者。
  • 计算EUSTAR-AI和EScSG-AI调整均值以捕捉疾病活动随时间的变化。
  • 主要结局为2年随访时Medsger严重度评分及其各条目Δ≥1的疾病进展。
  • 采用逻辑回归分析识别预测因素。

主要发现

  • 多因素分析中,EUSTAR-AI调整均值是2年内任何严重度累积的唯一预测因素。
  • EUSTAR-AI调整均值也是肺、心、皮肤和外周血管病变严重度累积的唯一预测因素。

关键数值与推荐

  • 疾病进展定义为2年随访时Medsger严重度评分Δ≥1。
  • 疾病进展也定义为2年随访时Medsger严重度评分各条目Δ≥1。

临床怎么用

  • 在系统性硬化症早期患者中,可采用EUSTAR-AI调整均值评估短期严重度累积风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The European Scleroderma Trials and Research Group (EUSTAR) recently developed a preliminarily revised activity index (AI) that performed better than the European Scleroderma Study Group Activity Index (EScSG-AI) in systemic sclerosis (SSc). OBJECTIVE: To assess the predictive value for short-term disease severity accrual of the EUSTAR-AI, as compared with those of the EScSG-AI and of known adverse prognostic factors. METHODS: Patients with SSc from the EUSTAR database with a disease duration from the onset of the first non-Raynaud sign/symptom ≤5 years and a baseline visit between 2003 and 2014 were first extracted. To capture the disease activity variations over time, EUSTAR-AI and EScSG-AI adjusted means were calculated. The primary outcome was disease progression defined as a Δ≥1 in the Medsger's severity score and in distinct items at the 2-year follow-up visit. Logistic regression analysis was carried out to identify predictive factors. RESULTS: 549 patients were enrolled. At multivariate analysis, the EUSTAR-AI adjusted mean was the only predictor of any severity accrual and of that of lung and heart, skin and peripheral vascular disease over 2 years. CONCLUSION: The adjusted mean EUSTAR-AI has the best predictive value for disease progression and development of severe organ involvement over time in SSc.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fasano S, Riccardi A, Messiniti V, et al. Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Ann Rheum Dis. 2019. PMID: 31422354. doi:10.1136/annrheumdis-2019-215787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。